More evidence for impact of lung cancer targeted therapy from practice-changing trial

4 diciembre 2014

For previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy, a new study confirms. This work involved 343 patients with previously untreated ALK-positive advanced non-small cell lung cancer. It showed that those patients who received crizotinib did better with respect to improvement in symptoms and delay in growth of the cancer than those on standard chemotherapy. Also the new targeted drug had no unexpected side effects.